Most uterine cancers have excellent five-year survival rates – up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 ...

"We’re in an exciting time for clinical research related to endometrial cancer, with a multitude of novel therapies being developed and in clinical trials right now. We’re making significant ...

Researchers say that in the course of developing a new model for ovarian cancer, they've developed additional evidence that serous uterine cancer possibly begins in the fallopian tubes, not the uterus ...

Characterization of copy number variations (CNV) patterns and pseudotime trajectories in high-grade serous ovarian cancer (HGSOC). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.

(RTTNews) - Acrivon Therapeutics, Inc. (ACVR) has unveiled promising Phase 2b data for its lead candidate ACR-368, showing a 52% confirmed overall response rate (cORR) in patients with serous ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Matulonis: Panos, ...

Drs Ursula A. Matulonis and Gini F. Fleming discuss the state of endometrial cancer, the role of immunotherapy, and priorities for research in this field. Drs Ursula A. Matulonis and Panagiotis A.

Uterine cancer develops in the tissues of the uterus, the hollow organ in the pelvis where a fetus could grow and develop during pregnancy. There are two main types of uterine cancer. The most common ...

Add Yahoo as a preferred source to see more of our stories on Google. “Uterine cancer is a cancer that starts in the uterus, the ‘womb’ or organ where a pregnancy grows,” says Vincent Wagner, MD, ...

Mesothelin-targeted CAR-NKT cells leveraged three recognition mechanisms, potentially limiting antigen escape and immunoediting compared with single-pathway CAR-T constructs. Complete tumor ...